BioArctic (BRCTF) and Neuren (NURPF) Turn Drug Royalties Into Dividends

On 25 and 26 August 2026, Neuren Pharmaceuticals Limited (NURPF) and BioArctic AB (BRCTF) described the same arrangement on separate calls: because their licensing partners carry the entire selling cost, the drug royalties they collect arrive with almost no cost attached, and both have now turned that money into a fixed shareholder payout [1][2].

---

A drug developer with no sales force carries almost no selling cost

Some biotech companies never build a commercial organization. They license an approved drug to a larger partner that handles selling, distribution, payer negotiation and promotion, and they collect a percentage of the partner's sales, known as a royalty. Neuren licensed DAYBUE, a treatment for Rett syndrome, to Acadia in the United States. BioArctic licensed Leqembi, a treatment for early Alzheimer's disease, to Eisai of Japan, which sells it worldwide. On both income statements the royalty is essentially the only line.

What changed is how predictable that royalty is and where it ends up. It used to be an uneven inflow that stayed on the balance sheet to support research, with dividends decided year by year. Now the partner absorbs the selling cost, so the developer's own expenses no longer scale with unit volume, and the royalty net of a small administrative charge is cash. The partner also publishes full-year sales guidance, which lets the developer estimate a year ahead what it will collect. Those two conditions are what make a percentage payout rule possible instead of a discretionary one. The royalty formula is already public — Neuren takes 10% on the first USD250m of DAYBUE sales and 12% above that [1] — so the structure does not depend on the drug or the therapeutic area and travels wherever a partner carries commercialization.

---

USD3m of half-year admin cost against a partner's USD160m quarterly SG&A

Neuren wrote its distribution rule down. It defined an available pool equal to DAYBUE royalty income less corporate and administrative costs less tax, set a payout range of 70% to 100%, and started at 90%, or USD0.15 per share, fully franked and payable on 7 October 2026 [1]. The cost base behind that rule is small: corporate and admin expense was USD3m for the half and was more than covered by USD5.6m of interest income, while cash ended the period at USD287m and funds the entire NNZ-2591 program together with future milestone payments, so the dividend does not draw on research [1]. The selling cost sits with the partner instead — Acadia reported USD160m of SG&A for the quarter against USD134m a year earlier [3].

BioArctic shows what the same structure looks like a year in. Second-quarter royalty income rose 12% sequentially to SEK179.4m on Eisai's global Leqembi sales of JPY29.3bn, about USD184m; the company had already paid a SEK177m dividend in June and still closed the quarter with roughly SEK2bn of cash [2]. Its explanation of the next leg of growth points at how the drug is administered rather than at prescriber reach: Japan was flat quarter over quarter at about USD38m, and management attributed that to hospital infusion capacity rather than demand, naming the coming subcutaneous formulation as the fix [2]. The same move is already visible at Acadia, where about 40% of US DAYBUE patients had switched to the STIX stick-pack by 30 June and the company credited 27 points of DAYBUE's 30% year-over-year growth to volume, primarily from that new format [3].

---

What the developer can distribute is set by the partner's selling pace

Customer access, distribution and pricing negotiation all stay on the partner's side, which compresses the developer's business down to one revenue line and a small administrative expense and makes capital distribution its main decision. Whether the royalty grows also depends on what the partner does with an already-approved molecule: a stick-pack replacing an oral solution, or a subcutaneous self-injection replacing an intravenous infusion, raises the reachable patient count and the revenue per patient within the existing indication, which moves value toward suppliers of formulation technology and delivery devices.

Crediting that growth entirely to the change in format would overstate it. Acadia's finance chief said the full-year guidance raise covers all forms of trofinetide available globally, including initial EU commercial sales expected in the fourth quarter; Acadia's own data also shows 55% of STIX users were existing patients switching over, and Neuren said plainly that switching does not affect its revenue [1][3]. The step further downstream did not hold up either: Option Care Health, the largest independent home and alternate-site infusion provider in the US, never mentions anti-amyloid infusion volume and says it dispenses both the intravenous and the subcutaneous forms of what it carries [4]. Two numbers will test this: whether Neuren's second-half royalty lands inside the USD53m-56m full-year guidance and triggers the 12% tier, and whether BioArctic's Japan sales move off roughly USD38m once the subcutaneous form is approved there.

---

Which companies this change may affect:

• Acadia Pharmaceuticals (ACAD): Sells DAYBUE in the US and carries exactly the selling cost Neuren does not, while running the same format switch on its own product, which puts Neuren's royalty and Acadia's selling pace at two ends of one line.
• Halozyme Therapeutics (HALO): Licenses the technology that converts intravenous drugs into subcutaneous injections and is paid a royalty each time a partner completes such a conversion, placing it directly downstream of the format change described here.
• Stevanato Group (STVN): Makes injection pens, autoinjectors and drug containment products, so turning approved molecules into forms patients administer themselves generates hardware orders for this kind of supplier; its named customers, however, are concentrated in obesity drugs and biosimilars, leaving the link to neurology and rare disease at the category level.

---

Sources

[1] Drillr · Neuren Pharmaceuticals (NURPF) · 2026-08-25 · First-half 2026 investor webinar, full transcript

"And we've identified what we're calling an available pool, which is the royalty income from DAYBUE, less our corporate and admin costs, less tax that becomes our available pool. And then we've set a 70% to 100% range of payout of that pool. And today, we started at the 90% level."

[2] Drillr · BioArctic AB (BRCTF) · 2026-08-26 · Q2 2026 earnings call, full transcript

[3] Drillr · Acadia Pharmaceuticals (ACAD) · 2026-08-04 · Q2 2026 earnings call, full transcript

[4] Drillr · Option Care Health (OPCH) · 2026-07-29 · Q2 2026 earnings call, full transcript

This is only meant to surface industry changes and companies you may have overlooked - it is not a stock recommendation.